AbbVie Announce Strategic Collaboration With Umoja Biopharma To Develop Novel In-Situ CAR-T Cell Therapies
Portfolio Pulse from Benzinga Newsdesk
AbbVie has entered into a strategic collaboration with Umoja Biopharma to develop novel in-situ CAR-T cell therapies for oncology. The partnership will combine Umoja's VivoVecTM gene delivery platform with AbbVie's oncology expertise to create CAR-T cell therapy candidates that are generated within the body.
January 04, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's collaboration with Umoja Biopharma to develop in-situ CAR-T cell therapies could enhance its oncology pipeline and potentially lead to breakthrough treatments.
The collaboration with Umoja Biopharma is likely to have a positive impact on AbbVie's stock in the short term due to the potential for developing innovative cancer treatments, which could significantly enhance AbbVie's oncology portfolio and future revenue streams.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80